Circulating Tumor DNA for Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer

LIAO Wang-jun; XU Fei

doi:10.12019/j.issn.1671-5144.2022.05.004

LIAO Wang-jun, XU Fei. Circulating Tumor DNA for Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(5): 268-271. DOI: 10.12019/j.issn.1671-5144.2022.05.004

Citation:

LIAO Wang-jun, XU Fei. Circulating Tumor DNA for Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(5): 268-271. DOI: 10.12019/j.issn.1671-5144.2022.05.004

Citation:

LIAO Wang-jun, XU Fei. Circulating Tumor DNA for Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(5): 268-271. DOI: 10.12019/j.issn.1671-5144.2022.05.004

Circulating Tumor DNA for Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer

Graphical Abstract

Abstract

FullText(HTML)

References (13)

Circulating Tumor DNA for Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer

Catalog

Export File

Citation

Format

Content